-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
5 views
Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Recurrent Respiratory Papillomatosis and opening up a $2 billion global market opportunity. Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026.
